TRAF1 antibody (AA 73-219)

Catalog No. ABIN7876671

The Mouse Monoclonal anti-TRAF1 antibody is suitable to detect TRAF1 in samples from Human. It has been validated for IHC (p).

Quick Overview for TRAF1 antibody (AA 73-219) (ABIN7876671)

Target: TRAF1 (TNF Receptor-Associated Factor 1 (TRAF1))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This TRAF1 antibody is un-conjugated

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Grade: Carrier-free

Clone: TRAF1-2770

Product Details anti-TRAF1 Antibody

Binding Specificity: AA 73-219

Purpose: TRAF1 Antibody (azide and preservative free)

Purification: Protein G affinity chromatography

Immunogen: A portion of amino acids 73-219 from the human protein was used as the immunogen for the TRAF1 antibody.

Isotype: IgG1, kappa

Application Details

Application Notes: Optimal dilution of the TRAF1 antibody should be determined by the researcher.

1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Preservative: Azide free

Storage: 4 °C,-20 °C

Storage Comment: Store the TRAF1 antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).

Target Details for TRAF1

Target: TRAF1 (TNF Receptor-Associated Factor 1 (TRAF1))

Alternative Name: TRAF1

Background: This mAb recognizes a protein of 52 kDa, which is identified as TNFR1 (TNFR-associated factor 1). CD30-positive lymphoproliferations of the skin comprise 30 % of all primary cutaneous T-cell lymphomas (CTCLs). Besides borderline cases this group includes lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large T-cell lymphoma (cALCL). Although the two entities overlap clinically, histopathologically, immunopathologically and genetically, they differ considerably in their prognosis. In particular, common feature of both cases is histologically the presence of atypical lymphoid CD30-positive T blasts and genetically a clonal T-cell-receptor rearrangement. However, both cases differ considerably in their clinical course: Lesions of LyP regress spontaneously, whereas those of cALCL persist and may progress and spread. Moreover, LyP patients do not benefit from an aggressive radio- and/or chemotherapeutic approach, in contrast to patients with cALCL. Besides, LyP and cALCL differ strongly in the expression of TRAF1 (tumor necrosis factor receptor (TNFR)-associated factor 1), a component of TNFR signaling: Whereas tumor cells of most LyP cases (ca. 84 %) show a strong TRAF1 expression, tumor cells of cALCL reveal TRAF1 expression in only a few cases (ca. 7 %). Antibody to TRAF1 is highly useful for the differentiation of LyP and cALCL in patients with cutaneous CD30-positive lymphoproliferations.

UniProt: Q13077

Pathways: NF-kappaB Signaling, Apoptosis, Cell-Cell Junction Organization, Asymmetric Protein Localization